



ASX/MEDIA RELEASE

7 September 2018

Sirtex Confirms Receipt of Balance of Scheme Consideration

Sydney, Australia

Sirtex Medical Limited (ASX:SRX) (**Sirtex**) confirms that, in accordance with the terms of the scheme implementation deed between Sirtex and CDH Genetech Limited and China Grand Pharmaceutical and Healthcare Holdings Limited (the **Bidders**) entered into on 14 June 2018 (**Scheme Implementation Deed**), the balance of the scheme consideration, being approximately \$1.7 billion, has been paid by the Bidders to the bank account in Australia into which they previously paid the total deposit of approximately \$220 million (which is an account opened by a major Australian bank as escrow agent for Sirtex and the Bidders).

If the proposed scheme of arrangement with the Bidders (**Scheme**) is approved and implemented, these funds will be used to pay the scheme consideration to Sirtex shareholders. If the Scheme does not proceed due to certain other events outlined in the Scheme Implementation Deed, Sirtex will be entitled to retain \$200 million (plus GST), with the balance returned to the Bidders. If the Scheme does not proceed due to other events, these funds will be returned in their entirety to the Bidders.

- ENDS -

About Sirtex Medical, www.sirtex.com

Sirtex Medical Limited (ASX:SRX) is an Australian based medical device company with global market coverage. Its core revenue producing technology, which has regulatory approvals, is a selective internal radiation therapy (SIRT), with clinically proven applications for liver cancer with approximately 92,000 doses supplied and administered at over 1,230 medical centres in more than 40 countries.

Investor Enquiries:

Mr Andrew McLean
CEO
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Investor/Media Enquiries:

Dr Tom Duthy
Global Head of Investor Relations &
Corporate Development
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

To subscribe to our email alert service for ASX Announcements, please visit:
<http://www.sirtex.com/au/investors/email-alerts/>

Follow us on Twitter: **@sirtexmedical**
Visit us on LinkedIn: **Sirtex Medical Limited**

Head Office
Level 33, 101 Miller Street
North Sydney, NSW 2060
Australia

Americas
300 Unicorn Park Drive
Woburn, MA 01801
United States

Europe, Middle East & Africa
Josef-Schumpeter-Allee 33
53227 Bonn
Germany

Asia Pacific
50 Science Park Road, #01-01
The Kendall Science Park II
Singapore 117406